Hengrui and IDEAYA Biosciences to Present Promising Lung Cancer Drug Data at IASLC 2025

Hengrui and IDEAYA Bioscience’s Publication for a Presentation at IASLC 2025

Announcement

Jiangsu Hengrui Pharmaceuticals co ltd a pharmaceutical company known for its technological and scientific innovation, and IDEAYA Biosciences Inc., a global precision medicine oncology company, showcased its publication for highlighting its oral presentation on IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer, organized by the International Association for the Study of Lung Cancer (WCLC). The event will be held from September 6-9, 2025, in Barcelona, Spain. The presentation will show safety and efficacy results in SCLC from its phase 1 trial, which Hengrui hosted in China for IDE849 (SHR-4849). A commendable delta-like ligand 3 (DLL3)-focusing topoisomerase-1 (TOP1) payload antibody drug conjugate (ADC). The DLL3 has been intensified in various solid tumor types in which the unmet need remains the same, including melanoma, non-small cell lung cancer (NSCLC), SCLC, and neuroendocrine tumors (NETs).

Hengrui and IDEAYA’s Presentation

IDEAYA will detail its poster presentation, including the data from its second published paper emphasizes merged pre-clinical synergy and mechanism data between IDE161 and TOP1 payload-based ADCs. It is a company’s proprietary, capable PARG inhibitor. This compilation holds the potential to improve the durability of TOP1 payload-related ADCs, also IDE034 and IDE849. The IDEAYA’s B7H3/PTK7 TOP1 ADC and the company’s alignment to the clinical development strategy of evaluation of rational combinations to work on enhancing and improving the clinical outcomes for cancer patients is a first priority.  

Further, the oral presentation is titled ‘a first-in-human phase 1 study of SHR-4849 (IDE849), a DLL3-directed antibody drug conjugate (ADC) in relapsed SCLC.’ The presentation will be showcased on Sunday, 7th September, around 4:45-6:00 PM (CET), in session OA6-Novel ADCs in SCLC. The poster presentation (2165) is titled ‘dual PARG-TOP1 Inhibition exacerbates DNA protein crosslinks and replication stress; A promising strategy for enhancing TOP1i-ADC efficacy’. The presenter is Reeja Maskey, PHD. The presentation will be held on Monday, 8th September, around 10:30 am- 12:00 pm (CET) in session P2.10 Metastatic non-small cell lung cancer, antibody drug conjugate and cytotoxic therapy.

The poster and oral presentation will be available at https://ir.ideayabio.com/events

Views and Statements

Chief medical officer at IDEAYA Biosciences, MD, PHD, Dr. Darrin Beaupre said, “We are proud of our partner Hengrui’s first-in-human phase 1 clinical safety and efficacy data presentation for IDE849 (SHR-4849) in SCLC patients at the WCLC 2025, as our company has advanced the worldwide development of IDE849.”